tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Intertrigo D007402 1 associated lipids
Impetigo D007169 3 associated lipids
Nocturnal Myoclonus Syndrome D020189 1 associated lipids
Pterygium D011625 3 associated lipids
Amyloid Neuropathies D017772 1 associated lipids
Mucinoses D017520 2 associated lipids
Carcinoma, Merkel Cell D015266 2 associated lipids
Nocturia D053158 1 associated lipids
Failed Back Surgery Syndrome D055111 3 associated lipids
Malacoplakia D008287 1 associated lipids
Myelitis D009187 1 associated lipids
Erythroplasia D004919 1 associated lipids
Migraine with Aura D020325 1 associated lipids
Hutchinson's Melanotic Freckle D018327 2 associated lipids
Lacerations D022125 1 associated lipids
Trauma, Nervous System D020196 2 associated lipids
Central Nervous System Viral Diseases D020805 1 associated lipids
Neuroaspergillosis D020953 2 associated lipids
Hepatopulmonary Syndrome D020065 1 associated lipids
Arm Injuries D001134 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Knoop C et al. Tacrolimus pharmacokinetics and dose monitoring after lung transplantation for cystic fibrosis and other conditions. 2005 Am. J. Transplant. pmid:15888057
Kim EJ et al. Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection. 2014 Am. J. Transplant. pmid:24354871
Kandaswamy R et al. A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients--an interim analysis. 2005 Am. J. Transplant. pmid:15888064
Cosio FG and Larson TS Cardiovascular disease after transplantation: do we know all of the variables? 2003 Am. J. Transplant. pmid:12859523
Krämer BK et al. Cardiovascular risk factors and estimated risk for CAD in a randomized trial comparing calcineurin inhibitors in renal transplantation. 2003 Am. J. Transplant. pmid:12859533
Xu H et al. The allo- and viral-specific immunosuppressive effect of belatacept, but not tacrolimus, attenuates with progressive T cell maturation. 2014 Am. J. Transplant. pmid:24472192
Qazi Y et al. Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data. 2017 Am. J. Transplant. pmid:27775865
Boudjema K et al. Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study. 2011 Am. J. Transplant. pmid:21466650
Coghill AE et al. Immunosuppressive Medications and Squamous Cell Skin Carcinoma: Nested Case-Control Study Within the Skin Cancer after Organ Transplant (SCOT) Cohort. 2016 Am. J. Transplant. pmid:26824445
Mehra MR et al. Immunosuppression in cardiac transplantation: science, common sense and the heart of the matter. 2006 Am. J. Transplant. pmid:16686745
Budde K et al. Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial. 2014 Am. J. Transplant. pmid:25278376
O'Grady JG et al. Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: poststudy surveillance to 3 years. 2007 Am. J. Transplant. pmid:17109723
Böhmig GA et al. Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trial. 2007 Am. J. Transplant. pmid:17109725
Ferguson R et al. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. 2011 Am. J. Transplant. pmid:21114656
Bouamar R et al. Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled clinical trials(†). 2013 Am. J. Transplant. pmid:23480233
Busque S et al. The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation. 2011 Am. J. Transplant. pmid:21943027
Hamdy AF et al. Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation. 2005 Am. J. Transplant. pmid:16162204
Kaufman DB et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction--long-term results. 2005 Am. J. Transplant. pmid:16162205
Naesens M et al. Tacrolimus exposure and evolution of renal allograft histology in the first year after transplantation. 2007 Am. J. Transplant. pmid:17608835
Schwarz A et al. Polyoma virus nephropathy in native kidneys after lung transplantation. 2005 Am. J. Transplant. pmid:16162212
Klintmalm GB Immunosuppression, generic drugs and the FDA. 2011 Am. J. Transplant. pmid:21794082
Shemesh E et al. The Medication Level Variability Index (MLVI) Predicts Poor Liver Transplant Outcomes: A Prospective Multi-Site Study. 2017 Am. J. Transplant. pmid:28321975
Forns X and Navasa M Cyclosporine A or tacrolimus for hepatitis C recurrence? An old debate. 2011 Am. J. Transplant. pmid:21797970
Wlodarczyk Z et al. Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. 2009 Am. J. Transplant. pmid:19681813
Chisholm-Burns MA et al. Immunosuppressant therapy adherence and graft failure among pediatric renal transplant recipients. 2009 Am. J. Transplant. pmid:19681814
Schold JD and Kaplan B AZA/tacrolimus is associated with similar outcomes as MMF/tacrolimus among renal transplant recipients. 2009 Am. J. Transplant. pmid:19681827
Troppmann C et al. Impact of portal venous pancreas graft drainage on kidney graft outcome in simultaneous pancreas-kidney recipients reported to UNOS. 2004 Am. J. Transplant. pmid:15023146
Pirenne J et al. Tolerance of liver transplant patients to strenuous physical activity in high-altitude. 2004 Am. J. Transplant. pmid:15023147
Heisel O et al. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. 2004 Am. J. Transplant. pmid:15023151
Hardinger KL et al. Pharmacokinetics of tacrolimus in kidney transplant recipients: twice daily versus once daily dosing. 2004 Am. J. Transplant. pmid:15023155
Suwelack B et al. Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. 2004 Am. J. Transplant. pmid:15023160
Busque S et al. Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients. 2009 Am. J. Transplant. pmid:19660021
Diaz-Siso JR et al. Initial experience of dual maintenance immunosuppression with steroid withdrawal in vascular composite tissue allotransplantation. 2015 Am. J. Transplant. pmid:25777324
Klintmalm GB et al. Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study. 2014 Am. J. Transplant. pmid:25041339
Oetting WS et al. Genomewide Association Study of Tacrolimus Concentrations in African American Kidney Transplant Recipients Identifies Multiple CYP3A5 Alleles. 2016 Am. J. Transplant. pmid:26485092
Badri P et al. Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. 2015 Am. J. Transplant. pmid:25708713
Larson TS et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. 2006 Am. J. Transplant. pmid:16468960
Vitko S et al. Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study. 2006 Am. J. Transplant. pmid:16468962
Woywodt A et al. Different preparations of tacrolimus and medication errors. 2008 Am. J. Transplant. pmid:18786238
Bourdeaux C et al. Living-related versus deceased donor pediatric liver transplantation: a multivariate analysis of technical and immunological complications in 235 recipients. 2007 Am. J. Transplant. pmid:17173657
Knechtle SJ et al. Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring. 2009 Am. J. Transplant. pmid:19344431
Rostaing L et al. Alefacept combined with tacrolimus, mycophenolate mofetil and steroids in de novo kidney transplantation: a randomized controlled trial. 2013 Am. J. Transplant. pmid:23730730
Grinyo JM et al. Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation. 2004 Am. J. Transplant. pmid:15268733
Schussler T et al. Severe hepatitis C infection in a renal transplant recipient following hepatitis C genotype mismatch transplant. 2004 Am. J. Transplant. pmid:15268744
Toso C et al. Sequential kidney/islet transplantation: efficacy and safety assessment of a steroid-free immunosuppression protocol. 2006 Am. J. Transplant. pmid:16611343
Ciancio G et al. Advantage of rapamycin over mycophenolate mofetil when used with tacrolimus for simultaneous pancreas kidney transplants: randomized, single-center trial at 10 years. 2012 Am. J. Transplant. pmid:22946986
Jacobson PA et al. Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. 2012 Am. J. Transplant. pmid:22947444
De Simone P et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. 2012 Am. J. Transplant. pmid:22882750
Fujishiro J et al. Influence of immunosuppression on alloresponse, inflammation and contractile function of graft after intestinal transplantation. 2010 Am. J. Transplant. pmid:20642681
Martinez F et al. High dose epoetin beta in the first weeks following renal transplantation and delayed graft function: Results of the Neo-PDGF Study. 2010 Am. J. Transplant. pmid:20642691